BridgeBio Pharma (BBIO) Free Cash Flow (2018 - 2026)
BridgeBio Pharma (BBIO) reported Free Cash Flow of -$197.3 million for Q1 2026, up 0.95% on a YoY basis from -$195.5 million in Q1 2025, and down 243.18% sequentially from -$57.5 million in Q4 2025.
BridgeBio Pharma (BBIO) Free Cash Flow (2018 - 2026) Analysis & Trends
BridgeBio Pharma (BBIO) has 9 years of Free Cash Flow data on file, last reported at -$197.3 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 0.95% year-over-year to -$197.3 million; the trailing twelve-month figure through Mar 2026 stood at -$445.1 million (up 10.98% YoY), and the FY2025 full-year result was -$447.0 million, up 14.2% from the prior year.
- Free Cash Flow declined to -$197.3 million in Q1 2026, from -$57.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $75.3 million in Q2 2024 to a low of -$220.2 million in Q1 2024.
- A 5-year average of -$124.6 million and a median of -$132.0 million in 2022 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 245.17% in 2023 and soared 166.2% in 2024, its largest moves.
- Tracing BBIO's Free Cash Flow over 5 years: stood at -$98.0 million in 2022, then decreased by 27.27% to -$124.7 million in 2023, then tumbled by 56.61% to -$195.3 million in 2024, then soared by 70.56% to -$57.5 million in 2025, then tumbled by 243.18% to -$197.3 million in 2026.
- Business Quant data shows BBIO's Free Cash Flow at -$197.3 million in Q1 2026, -$57.5 million in Q4 2025, and -$109.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | BridgeBio Pharma | 16.15 Bn | 15.22 Bn | 184.58 Mn | -197.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -197.35 Mn |
| Mar 31, 2026 | -197.35 Mn |
| Dec 31, 2025 | -57.51 Mn |
| Dec 31, 2025 | -57.51 Mn |
| Sep 30, 2025 | -109.59 Mn |
| Sep 30, 2025 | -109.59 Mn |
| Jun 30, 2025 | -80.68 Mn |
| Jun 30, 2025 | -80.68 Mn |
| Mar 31, 2025 | -199.24 Mn |
| Mar 31, 2025 | -199.24 Mn |
| Dec 31, 2024 | -195.33 Mn |
| Dec 31, 2024 | -195.33 Mn |
| Sep 30, 2024 | -180.77 Mn |
| Sep 30, 2024 | -180.77 Mn |
| Jun 30, 2024 | 75.33 Mn |
| Jun 30, 2024 | 75.33 Mn |
| Mar 31, 2024 | -220.23 Mn |
| Mar 31, 2024 | -220.23 Mn |
| Dec 31, 2023 | -124.73 Mn |
| Dec 31, 2023 | -124.73 Mn |